XyloCor Therapeutics

Executive Summary

XyloCor Therapeutics is a clinical-stage biotechnology company based in Philadelphia, PA, developing proprietary gene therapies for advanced coronary artery disease (CAD). Founded in 2016, the company leverages technology licensed from Weill Cornell Medical College to address the significant unmet need in patients with refractory angina and severe CAD who are not suitable for revascularization. Its lead candidate, XC001, is a novel gene therapy designed to stimulate angiogenesis by delivering the VEGF-D gene directly into the heart muscle, aiming to improve blood flow and reduce symptoms. The company has completed Phase 1/2 clinical trials evaluating safety and efficacy, with promising early data suggesting improved exercise capacity and reduced angina frequency. XyloCor represents a potential paradigm shift in the treatment of advanced CAD, offering a one-time biologic alternative to conventional therapies. As a private firm, it has not disclosed total funding, but its progress positions it for potential regulatory milestones and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for XC00160% success
• Q2 2026Series B/C financing round70% success
• Q1 2027FDA Type B meeting for Phase 3 planning80% success